Tabuteau Herriot, chief executive officer of Axsome Therapeutics (AXSM), has been a consistent seller of company stock over the past year, with Form 4 filings showing 38 total transactions and zero open-market purchases. The aggregate sell value across all filings reached approximately $100 million, and the pattern has intensified recently: 12 of the 13 most recent trades were open-market sales, with no buys recorded in that window. The selling is clustered in large blocks—individual dispositions between November 2025 and July 2026 ranged from roughly $1.6 million to $13.5 million—with the largest single sale of $13.48 million occurring on January 5, 2026.
The transaction structure reveals a mechanical component beneath the selling. Each sale is paired with an option exercise (code M) of modest value, typically $85,000 to $631,000, suggesting the shares sold were acquired through exercised options rather than newly purchased stock. The gap between exercise values and sale proceeds is substantial—for example, on July 1, 2026, Herriot sold $11.9 million in stock while exercising options worth just $245,847. This pattern, repeated across every trading date, indicates the CEO is liquidating vested equity rather than adding to his position. Two zero-value grants (code A) in February and April 2026 represent compensation awards, not conviction buys.
The absence of any open-market purchases (code P) across the entire filing history, combined with the steady cadence of large sales, points to a clear directional bias: Herriot is a net seller of AXSM stock. The sales are spread across multiple months—November 2025, December 2025, January 2026, February 2026, June 2026, and July 2026—rather than concentrated in a single event, suggesting a systematic approach to monetizing equity rather than a one-off reaction. With total sell value exceeding $100 million and zero buy value, the insider activity at Axsome is unambiguously skewed toward distribution.
AI-assisted summary